<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230057</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001235</org_study_id>
    <nct_id>NCT04230057</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Antitumor B in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics Study of Antitumor B in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the single-dose oral pharmacokinetics of an herbal&#xD;
      supplement - Antitumor B - in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six&#xD;
      plants: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus,&#xD;
      Dictamnus dasycarpus, and Dioscorea bulbifera. ATB is available as 300 mg tablets and has&#xD;
      been traditionally used in China for dysplasia (dose 4-8 tables/ twice daily). Several&#xD;
      studies in rodents and humans have been published demonstrating the chemopreventive activity&#xD;
      of ATB against various cancers (e.g. lung, esophageal and oral). However, the investigators&#xD;
      currently do not know what pharmacologically relevant concentration levels can be achieved&#xD;
      systemically for different components of ATB in humans. Since it is a complex herbal mixture&#xD;
      containing various key active components (KACs), relative levels of KACs in the ATB mixture&#xD;
      can influence the bioavailability and pharmacokinetic of the individual KACs. The proposed&#xD;
      study aim to estimate the plasma concentration of four key active components in a tablet with&#xD;
      a chemical-defined ATB mixture. The investigators are interested in doing a human single-dose&#xD;
      (8 tablets once) full pharmacokinetic study of ATB tablets. The investigators plan to collect&#xD;
      9 blood and 9 saliva samples from 8 healthy volunteers over a period of 24 hours (at&#xD;
      pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours) to&#xD;
&#xD;
        1. determine the saliva and plasma concentration of four key constituents of ATB (matrine,&#xD;
           dictamnine, maackiain, fraxinellone) and&#xD;
&#xD;
        2. develop the in vivo correlation between plasma and saliva concentrations&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of matrine, dictamnine, maackiain and fraxinellone in plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Maximum (peak) observed drug concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of matrine, dictamnine, maackiain and fraxinellone in saliva</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Maximum (peak) observed drug concentration in saiva</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of matrine, dictamnine, maackiain and fraxinellone in plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Time of Maximum (peak) observed drug concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of matrine, dictamnine, maackiain and fraxinellone in saliva</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Time of Maximum (peak) observed drug concentration in saliva</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of matrine, dictamnine, maackiain and fraxinellone in plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Area under the curve of plasma concentration-time profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of matrine, dictamnine, maackiain and fraxinellone in saliva</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>Area under the curve of saliva concentration-time profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma-saliva IVIVC</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose</time_frame>
    <description>In vivo-in vivo correlation established between plasma and saliva concentrations</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <description>In good general health and feeling well (no diagnosed disorders/illnesses)&#xD;
At least 18 years old&#xD;
BMI in the range of 18-29.9 kg/m²&#xD;
No known history of substance abuse&#xD;
No known allergies to food/drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antitumor B</intervention_name>
    <description>Single dose 2400 mg</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <other_name>Zeng Sheng Ping</other_name>
    <other_name>ACAPHA</other_name>
    <other_name>ATB</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects in University of Houston and nearby area&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A potential subject must meet all the following inclusion criteria to be eligible to&#xD;
             participate in the study.&#xD;
&#xD;
               1. Health questionnaire filled on the day of recruitment, after signing the written&#xD;
                  consent form&#xD;
&#xD;
               2. Participants must receive administration of study agent within 21-28 calendar&#xD;
                  days of being selected as subject after screening procedure is completed&#xD;
&#xD;
               3. Healthy male or female subjects aged ≥18 and ≤40 years of age&#xD;
&#xD;
               4. Subjects must have a body mass index (BMI) between 18.0-29.9 kg/m² inclusive&#xD;
&#xD;
               5. CBC/differential obtained within 14 calendar days prior to selection as subject&#xD;
                  for drug administration , with adequate bone marrow function defined as follows:&#xD;
                  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3;&#xD;
                  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to&#xD;
                  achieve Hgb&#xD;
&#xD;
                  ≥ 8.0 g/dl is acceptable.);&#xD;
&#xD;
               6. Adequate renal and hepatic function within 14 calendar days prior to selection as&#xD;
                  subject for drug administration defined as follows: Serum creatinine &lt; 1.5 mg/dl&#xD;
                  or creatinine clearance (CCr) ≥ 50 ml/min within 14 calendar days prior to&#xD;
                  selection as subject for drug administration, determined by 24-hour collection or&#xD;
                  estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)]&#xD;
                  [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)&#xD;
&#xD;
               7. Total bilirubin &lt; 2 x the institutional Upper limit of Normal range (ULN) within&#xD;
                  14 calendar days prior to selection as subject for drug administration&#xD;
&#xD;
               8. AST or ALT ≤ 3 x the institutional ULN within 14 calendar days prior to selection&#xD;
                  as subject for drug administration&#xD;
&#xD;
               9. ALP or GGT ≤ 2.5 x the institutional ULN within 14 calendar days prior to&#xD;
                  selection as subject for drug administration&#xD;
&#xD;
              10. Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior&#xD;
                  to selection as subject for drug administration, with the following required&#xD;
                  parameters: Magnesium: &gt; 0.9 mg/dl or &lt; 3 mg/dl; Calcium: &gt; 7 mg/dl or &lt; 12.5&#xD;
                  mg/dl; Glucose: &gt; 40 mg/dl or &lt; 250 mg/dl; Potassium: &gt; 3 mmol/L or &lt; 6 mmol/L;&#xD;
                  Sodium: &gt; 130 mmol/L or &lt; 155 mmol/L.&#xD;
&#xD;
              11. Participant must have active health insurance coverage at the time of study&#xD;
&#xD;
              12. Participants must be able to understand study-specific information and&#xD;
                  instructions in English.&#xD;
&#xD;
              13. Participant must be willing to fully comply with study procedures and&#xD;
                  restrictions.&#xD;
&#xD;
              14. Participant must be able to provide written, personally signed, and dated&#xD;
                  informed consent to participate in the study, in accordance with the ICH Good&#xD;
                  Clinical Practice (GCP) Guideline E6 (1996) and applicable regulations, before&#xD;
                  completing any studyrelated procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of active liver disease or cancer.&#xD;
&#xD;
          2. Severe current or recurrent comorbidity such as (e.g., cardiovascular, haematological,&#xD;
             neurological, endocrine, renal, liver, GI, HIV-AIDS, or other conditions such as&#xD;
             cancer) that could affect the absorption and/or disposition of ATB&#xD;
&#xD;
          3. Any disease/illness diagnosed by a licensed physician.&#xD;
&#xD;
          4. Blood report positive for HIV and/or Hepatitis B and C tests&#xD;
&#xD;
          5. Has had an acute illness within two weeks prior to screening.&#xD;
&#xD;
          6. Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or&#xD;
             fetus.&#xD;
&#xD;
          7. Concurrent use of any prescription medication (including medicinal botanical) except&#xD;
             birth control pills, over the counter medication and supplements except Vitamins and&#xD;
             mineral supplements, or herbal supplements in form of herbal mixtures, teas or&#xD;
             individual compounds (such as querctein, curcumin, echinacea, flaxseed, ginseng,&#xD;
             ginkgo, soy etc.) that the study PI believes could potentially impact the&#xD;
             results/objectives of this study.&#xD;
&#xD;
          8. Concurrent use of recreational drugs or alcohol during the study (self-declared by&#xD;
             study participants)&#xD;
&#xD;
          9. Prisoners&#xD;
&#xD;
         10. Economically and/or educationally disadvantaged persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Hu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Houston, College of Pharmacy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.youtube.com/watch?v=IByBdYGRQig</url>
    <description>Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 1 of 3</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=qmRewC7kkcU</url>
    <description>Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 2 of 3</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=jMXDUFo5LoE</url>
    <description>Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 3 of 3</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT00522197?term=acapha&amp;rank=1</url>
    <description>ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia</description>
  </link>
  <reference>
    <citation>Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP. [Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]. Zhonghua Zhong Liu Za Zhi. 1988 May;10(3):161-6. Chinese.</citation>
    <PMID>3219974</PMID>
  </reference>
  <reference>
    <citation>Lin P, Zhang J, Rong Z, Han R, Xu S, Gao R, Ding Z, Wang J, Feng H, Cao S. Studies on medicamentous inhibitory therapy for esophageal precancerous lesions--3- and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. Proc Chin Acad Med Sci Peking Union Med Coll. 1990;5(3):121-9.</citation>
    <PMID>2098764</PMID>
  </reference>
  <reference>
    <citation>Lin P. [Medicamentous inhibitory therapy of precancerous lesions of the esophagus--3 and 5 year inhibitory effect of antitumor B, retinamide and riboflavin]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1990 Aug;12(4):235-45. Chinese.</citation>
    <PMID>2147582</PMID>
  </reference>
  <reference>
    <citation>Sun Z, Guan X, Li N, Liu X, Chen X. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol. 2010 Feb;46(2):105-10. doi: 10.1016/j.oraloncology.2009.06.004. Epub 2009 Dec 21.</citation>
    <PMID>20022553</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Wang Y, Yao R, Li J, Yan Y, La Regina M, Lemon WL, Grubbs CJ, Lubet RA, You M. Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene. 2004 May 6;23(21):3841-50.</citation>
    <PMID>15021904</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, You M. Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis. Mol Carcinog. 2013 Jan;52(1):49-56. doi: 10.1002/mc.20877. Epub 2011 Nov 15.</citation>
    <PMID>22086836</PMID>
  </reference>
  <reference>
    <citation>Yin T, Yang G, Ma Y, Xu B, Hu M, You M, Gao S. Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping(Antitumor B). J Ethnopharmacol. 2015 Aug 22;172:195-201. doi: 10.1016/j.jep.2015.06.019. Epub 2015 Jun 20.</citation>
    <PMID>26099633</PMID>
  </reference>
  <reference>
    <citation>Gao S, Yang Z, Yin T, You M, Hu M. Validated LC-MS/MS method for the determination of maackiain and its sulfate and glucuronide in blood: application to pharmacokinetic and disposition studies. J Pharm Biomed Anal. 2011 May 15;55(2):288-93. doi: 10.1016/j.jpba.2011.01.015. Epub 2011 Jan 22.</citation>
    <PMID>21349678</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Gao S, Yin T, Kulkarni KH, Teng Y, You M, Hu M. Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method. J Pharm Biomed Anal. 2010 Apr 6;51(5):1120-7. doi: 10.1016/j.jpba.2009.11.020. Epub 2009 Nov 26.</citation>
    <PMID>20034755</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 11, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Houston</investigator_affiliation>
    <investigator_full_name>Ming Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Antitumor B</keyword>
  <keyword>healthy volunteer</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

